Home › Legal › Cannabis Medical Program Qualifying Conditions in South Africa
⚐ Flag an error How this page was made
Also known as: SAHPRA medical cannabis access · Section 21 cannabis authorisation · South African medical cannabis eligibility

Cannabis Medical Program Qualifying Conditions in South Africa

South Africa has no statutory qualifying-conditions list; medical access runs through SAHPRA evaluation.

Automated fact-check pass
3 cited sources
Published
Last reviewed
How this page was made

This article is general information, not legal advice. Laws change; check current rules with official sources or a lawyer.

↯ The honest take

South Africa does not have a 'medical cannabis program' in the US sense. There is no official list of qualifying conditions, no patient card, and no registry. Instead, a doctor applies to SAHPRA (the medicines regulator) for permission to prescribe an unregistered cannabis product to a named patient. The decision is clinical, not formulaic. Clinics advertising 'qualifying conditions' are usually copying lists from elsewhere with no legal force.

South Africa has no official qualifying-conditions list

South Africa does not operate a US-style medical cannabis program. There is no statutory list of qualifying conditions, no state-issued patient card, and no public patient registry Strong evidence. SAHPRA, the national medicines regulator, controls access to cannabis-containing medicines under the Medicines and Related Substances Act 101 of 1965 Strong evidence.

This is the single most misunderstood point in South African cannabis policy. Clinics and dispensaries that advertise 'qualifying conditions' are typically reproducing internal clinical criteria or copying lists from other jurisdictions (Israel, Germany, US states). Those lists have no force of law in South Africa Strong evidence. Any entity offering a 'medical cannabis licence,' 'patient card,' or 'pre-approved conditions' outside the two legal routes described below is operating outside the regulatory framework.

There are two legal routes to cannabis-based medicine in South Africa:

1. Registered/scheduled CBD products. In 2019 the Minister of Health issued an exclusion notice and amended schedules so that low-dose cannabidiol preparations (broadly: ≤20 mg/day CBD, with minimal THC, in pack sizes ≤600 mg) became available as Schedule 0 or Schedule 4, depending on the claim and concentration Strong evidence. The original 12-month exclusion notice has been extended since then; check the current Government Gazette for the version in force, as the notice requires periodic renewal.

2. Section 21 of Act 101 of 1965 (SAHPRA authorisation). For any cannabis-based medicine stronger than the scheduled CBD products — THC-containing oils, dried flower for medical use, or specific CBD doses outside the schedule — a registered medical practitioner must apply to SAHPRA for authorisation to prescribe an unregistered medicine for a named patient Strong evidence [1]. SAHPRA evaluates each application on clinical merits submitted by the doctor. There is no third 'medical card' route.

Conditions doctors commonly motivate for

Because the decision is clinician-led and case-by-case, there is no statutory 'list.' The practical set of conditions reflects those for which South African prescribers can build an evidence-based motivation. International clinical evidence reviews (US National Academies, Cochrane) most commonly support applications for:

A prescriber may motivate for other indications, but approval turns on the published evidence for that specific condition. Claims that cannabis 'cures' or 'treats' cancer, autism, or HIV in any definitive sense are not supported by controlled clinical evidence No data. Anecdotal reports or lab-dish studies do not constitute a basis for a Section 21 application.

What a Section 21 application requires

The doctor — not the patient — submits the Section 21 application to SAHPRA Strong evidence [1]. SAHPRA's process typically requires:

Authorisations are product-specific and time-limited (typically 6–12 months, subject to renewal). They do not confer any right to grow cannabis, possess flower outside the dispensed product, or share medicine with others Strong evidence. Each authorization is tied to a named patient and a named prescriber.

Private adult use is separate from medical access

In Minister of Justice and Constitutional Development v Prince (2018), South Africa's Constitutional Court decriminalised private use, possession, and cultivation of cannabis by adults in private spaces Strong evidence. The Cannabis for Private Purposes Act 7 of 2024 was signed into law in May 2024 and codifies this private adult use, but explicitly does not create a commercial recreational market and does not change the medical framework Strong evidence.

Medical cannabis access still runs through SAHPRA Section 21 applications or scheduled CBD products. Personal private cultivation under the Prince judgment is a separate legal track and is not a substitute for a Section 21 prescription if you want pharmaceutical-grade product quality assurance or legal supply through a licensed clinic Strong evidence. The two pathways exist in parallel but do not overlap.

Recent changes and what to watch

Information last verified: 31 October 2026. Regulatory frameworks change; always confirm against the current Government Gazette, SAHPRA website, and current ministerial notices before acting on this information.

Not legal or medical advice

This article is informational and reflects the regulatory framework as understood at the date of verification above. It is not legal advice, not medical advice, and not a substitute for professional counsel.

If you are seeking medical cannabis in South Africa, consult a registered medical practitioner with experience submitting Section 21 applications. If you have a legal question — possession charges, cultivation disputes, regulatory compliance, or licensing — consult a South African attorney licensed to practise in that area.

Sources

  1. Peer-reviewed National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Press, 2017.
  2. Peer-reviewed Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456-2473.
  3. Government Constitutional Court of South Africa. Minister of Justice and Constitutional Development and Others v Prince (CCT108/17) [2018] ZACC 30.

How this page was made

Generation history

Oct 31, 2026
Fact-check pass — raised 8 flags
Oct 31, 2026
Revision
Jun 6, 2026
Fact-check pass — raised 2 flags
Jun 6, 2026
Initial draft

Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.